FDA clears fruit-flavored vapes, relaxes enforcement on black-market products with pending premarket applications Critics say policies clear the way for major tobacco companies to enter fruit-flavored vape market

The Cancer History Project debuts first de novo book; meanwhile, FDA snafus continue

In last week’s issue of The Cancer Letter, the cover story featured something special: The first de novo book published by The Cancer History Project. The book, “Backwater to Blockbuster: St. Jude Children’s Research Hospital,” co-written by Charles J. Sherr and William E. Evans, chronicles the previously untold story of St. Jude Children’s Research Hospital and its rise to becoming a global leader in pediatric cancer research.

May 20, 2026

Regulatory News

After a year-long reign over tumult at FDA, Makary heads for the exit
Fruit-flavored e-cigs were the final blow for the commissioner

The immediate impetus for FDA Commissioner Marty Makary’s exit from the top job at FDA is arguably less significant than the legacy of dysfunction he leaves behind.

May 15, 2026

Vol.52 No.19

By Claire Marie Porter

Drugs & Targets

FDA approves oral combination Inqovi plus venetoclax for newly diagnosed AML

FDA approved an oral combination of Inqovi (decitabine and cedazuridine) plus venetoclax as a treatment for adults with newly diagnosed acute myeloid leukemia who are 75 years or older or who are ineligible for intensive induction chemotherapy.

May 15, 2026

Vol.52 No.19

Drugs & Targets

Bizengri gets FDA approval for bile cancer, becomes seventh drug approved under the priority voucher program

FDA approved Bizengri (zenocutuzumab-zbco), a drug that treats NRG1 fusion-positive cholangiocarcinoma.

May 15, 2026

Vol.52 No.19

Drugs & Targets

FDA clears AI digital pathology risk stratification tool in breast cancer

FDA cleared ArteraAI Breast, a multimodal AI-based prognostic and predictive cancer test, for use in patients with early-stage, hormone receptor-positive HER2-negative invasive breast cancer.

May 15, 2026

Vol.52 No.19

Drugs & Targets

FDA grants Fast Track designation to Suplexa in MSI-H CRC

FDA granted Fast Track designation to Suplexa, a differentiated, non-engineered autologous treatment, for the treatment of patients with colorectal cancer of the MSI-H phenotype.

May 15, 2026

Vol.52 No.19

FDA clears fruit-flavored vapes, relaxes enforcement on black-market products with pending premarket applications

Critics say policies clear the way for major tobacco companies to enter fruit-flavored vape market

YOU MAY BE INTERESTED IN

The Cancer History Project debuts first de novo book; meanwhile, FDA snafus continue

After a year-long reign over tumult at FDA, Makary heads for the exit
Fruit-flavored e-cigs were the final blow for the commissioner

FDA approves oral combination Inqovi plus venetoclax for newly diagnosed AML

Bizengri gets FDA approval for bile cancer, becomes seventh drug approved under the priority voucher program

FDA clears AI digital pathology risk stratification tool in breast cancer

FDA grants Fast Track designation to Suplexa in MSI-H CRC

Renew today!

Subscriber content

Never miss an issue!

Login

FDA clears fruit-flavored vapes, relaxes enforcement on black-market products with pending premarket applications

Critics say policies clear the way for major tobacco companies to enter fruit-flavored vape market

YOU MAY BE INTERESTED IN

The Cancer History Project debuts first de novo book; meanwhile, FDA snafus continue

After a year-long reign over tumult at FDA, Makary heads for the exitFruit-flavored e-cigs were the final blow for the commissioner

FDA approves oral combination Inqovi plus venetoclax for newly diagnosed AML

Bizengri gets FDA approval for bile cancer, becomes seventh drug approved under the priority voucher program

FDA clears AI digital pathology risk stratification tool in breast cancer

FDA grants Fast Track designation to Suplexa in MSI-H CRC

Never miss an issue!

Login

After a year-long reign over tumult at FDA, Makary heads for the exit
Fruit-flavored e-cigs were the final blow for the commissioner